Louisiana State Employees Retirement System Purchases Shares of 60,400 Hims & Hers Health, Inc. $HIMS

Louisiana State Employees Retirement System acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 60,400 shares of the company’s stock, valued at approximately $1,254,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Hims & Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after acquiring an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health during the first quarter worth about $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after purchasing an additional 687 shares during the period. Amundi raised its holdings in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after purchasing an additional 522 shares during the period. Finally, California Public Employees Retirement System raised its holdings in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after purchasing an additional 29,471 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 18,197 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91. Following the transaction, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at approximately $9,675,443.63. The trade was a 6.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the transaction, the insider owned 181,861 shares of the company’s stock, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 163,973 shares of company stock valued at $4,859,194 over the last three months. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $36.75 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43. The company has a market capitalization of $8.51 billion, a price-to-earnings ratio of -408.32, a PEG ratio of 52.60 and a beta of 2.35. The business has a 50-day moving average of $28.61 and a 200-day moving average of $26.38.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.20 earnings per share. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on HIMS shares. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 5th. Barclays lifted their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Finally, TD Cowen dropped their price objective on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.63.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.